GSK-3745417
- Generic Name
- GSK-3745417
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT05424380
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT03843359
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath